Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-11-19
1993-10-26
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514415, 514429, 514471, 514869, A61K 3140, A61K 31405, A61K 3134
Patent
active
052566870
ABSTRACT:
The invention relates to a pharmaceutical composition comprising an angiotensin converting enzyme inhibitor (trandolpril or pamipril) and a loop diuretic (Furosemide or piretanide), and to their use for the treatment of high blood pressure.
REFERENCES:
patent: 4217347 (1980-08-01), Horovitz et al.
patent: 4374829 (1983-02-01), Harris et al.
patent: 4564625 (1986-01-01), Muschaweck et al.
R. H. A. Becker et al., "Loop Diuretics Combined with an Ace Inhibitor for Treatment of Hypertension: A Study with Furosemide, Piretanide, and Ramipril in Spontaneously Hypertensive Rats", Journal of Cardiovascular Pharmacology, 1989, 13, pp. S35-S39.
Metzger et al., "2-[N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S, 3S, 5S)-2-azabicyclo[3.3.0]octane-3-carboxylic Acid (HOE498)--A New and Highly Effective Angiotension I Converting Enzyme Inhibitor", Drug Research, vol., 34 (II), NR. 10b, pp. 1402-1406 (1984).
Gavras et al., "Antihypertensive Effect of the New Oral Antiotension Converting Enzyme Inhibitor MK-421", The Lancet, Sep. 12, 1981, 543-546.
Lederle et al., "Antihypertensiver Effect des Converting-Enzym-Inhibitors Captopril bei essentieller Hypertonie", Therapiewoche 29, (1979), p. 7746.
Studer et al., "Captopril (SQ 14225) bei terapieresistenter Hypertonie", Terapiewoche 29, 45 (1979), p. 7749.
Vlasses et al. "Comparative Antihypertensive Effects of Enalapril Maleate And Hydrochlorothiazide, Along And In Combination", J. Clin. Pharmocol. 23:227-233 (1983).
Chem. Abst. 101, p. 35 (1984).
Patent Abstract of Japan, vol. 6, No. 24 (C-91)/902, Feb. 12, 1982.
MacGregor, et al., Captopril In Essential Hypertension: Contrasting Effects of Adding Hydrochlorothiazide or Propranolol, British Medical Journal. vol. 284, pp. 693-696 (Mar. 6, 1982).
Chiu, et al., Acute Blood Pressure and Urinary Responses To Single Single Dose Combinations of Captopril and Diuretics In Conscious Spontaneously Hypertensive Rats, J. Pharm. Pharmacol., vol. 37, pp. 105-109 (1985).
Brunner et al., Enhancements By Diuretics Of The Antihypertensive Action of Long-Term Angiotensive Converting Enzyme Blockade. Clinical and Experimental Hypertension, vol. 2 (3&4), pp. 639-657 (1980).
Scholkens et al., Cardiovascular And Antihypertensive Activities Of The Novel Nonsulfhydryl Converting Enzyme Inhibitor 2-[N-.upsilon.(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S, 3S, 5S) 2-azabicyclo [3.3.0] octane-3-carboxylic Acid (HOE-498), Drug Research, vol. 34 (II), NR. 10B, pp. 1417-1425 (1984).
Becker Reinhard
Geiger Rolf
Henning Rainer
Teetz Volker
Urbach Hansjorg
Criares T. J.
Hoechst Aktiengesellschaft
Waddell Frederick E.
LandOfFree
Pharmaceutical composition for the treatment of high blood press does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for the treatment of high blood press, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for the treatment of high blood press will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-959726